🎉 Celebrating 1 Year of Innovation at Hopewell! Since opening in 2024, our flagship U.S. biologics manufacturing and clinical R&D facility has become a cornerstone of BeOne’s global network—accelerating cancer innovation, advancing our pipeline, and expanding access for

Each year in the U.S., nearly 2 million people are diagnosed with cancer. Globally, it’s the second leading cause of death—and by 2040, cases are projected to surge to 30 million, with more than 15 million deaths. At BeOne, we’re confronting this staggering challenge head-on.

#News for #Investors and #Media: BeOne Medicines has received a positive CHMP opinion for our immunotherapy in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of patients with resectable

#News for #Investors and #Media: The EMA has granted PRIME designation to BeOne’s investigational BTK degrader in WM, recognizing its potential to meet an urgent need for patients with limited options. We are working to bring innovative treatments to the B-cell malignancy

BeOne announces second quarter 2025 financial results and business updates. Read the press release here: ir.beonemedicines.com/news/beone-med…

In our latest episode of Cancer Has No Borders Podcast, we explore the persistent inequalities in cancer care across Europe. Cancer mortality rates in parts of Eastern Europe are nearly 50% higher than in Western Europe - What will it take to close the gap? In this episode,

At BeOne, we’re proud to have a strong and growing presence in the U.S. – a vital hub powering our global mission: to eliminate cancer everywhere and for everyone. With 1,800+ colleagues nationwide and thousands of patients enrolled in our clinical trials, we’re advancing

“Five years to live.” That was the prognosis Bruce received when he was diagnosed with CLL in 2009. Sixteen years later, Bruce is still here. Thanks to the advances in treatment and the unwavering support of his wife, Mary Elaine, who stood by him every step of the way. Her

#News for #Investors and #Media: Even small changes – like reducing the daily pill burden – can make a real difference for patients with blood cancer. This is why we are pleased to share that our BTK inhibitor has now received European Commission approval for a new tablet

We look forward to supporting CLL Society Inc.'s upcoming webinar on the unique challenges and considerations of CLL / SLL among veterans, taking place Thursday, August 28. This free, virtual event will address the higher prevalence of CLL in veterans, the VA’s recognition of CLL as

Our General Manager of North America, Matt Shaulis, joined The Bio Report to share how our U.S. efforts are helping strengthen a global manufacturing footprint—accelerating innovation, reducing costs, and expanding access to cancer therapies. From small molecules to biologics,

BeOne Medicines has entered into an up to $950 million royalty purchase agreement with Royalty Pharma for IMDELLTRA®, a first-in-class bispecific T-cell engager (BiTE). This agreement accelerates value realization for BeOne, providing increased operational and strategic

#News for #Investors and #Media: The European Commission has approved our immunotherapy in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for adult patients with resectable non-small cell lung cancer (#NSCLC) at

#News for #Investors and #Media: EMA grants orphan drug designation to our BTK degrader for R/R WM —a rare B-cell cancer with limited treatment options. Learn more about our focus on hematology: beonemedicines.com/science/resear…

#News for #Investors and #Media: Mantle cell lymphoma (MCL) is rare, aggressive, and often diagnosed late – leaving patients with few options. Today, we announced positive topline results for our next-generation BCL2 inhibitor in relapsed/refractory (R/R) MCL. Explore how we’re

🌍 Today is World CLL Day! #WCLLD25 focuses on strengthening #HealthLiteracy, raising #CLL awareness, and empowering better decisions. Let’s build a global community of support and advocacy. 👉 Get involved: wclld.org/how-to-get-inv… #HealthDecisions #ThriveWithCLL

Many patients with CLL feel uniformed and excluded from decisions about their care during active monitoring, causing anxiety. Let’s bridge the gap in education and support. Read the Call-To-Action Report: clladvocates.net/program/cll-ac… #WCLLD25 #NavigatIngCLLTogether